Page 20 - 南京医科大学学报自然科学版

第43卷第5期
·602 · 南 京 医 科 大 学 学 报 2023年5月

（4）：1811-1822 geting DLL3 kill effectively small cell lung cancer cells in
［17］ HUANG C F，WANG S C，CHANG W T，et al. Lower pro⁃ vitro and in vivo［J］. J Leukoc Biol，2022，112（4）：901-
tein expression levels of MHC class I chain⁃related gene 911
a in hepatocellular carcinoma are at high risk of recur⁃ ［29］ LIU E，TONG Y，DOTTI G，et al. Cord blood NK cells en⁃
rence after surgical resection［J］. Sci Rep，2018，8（1）： gineered to express IL ⁃ 15 and a CD19 ⁃ targeted CAR
15821 show long⁃term persistence and potent antitumor activity
［18］ LIU R，LUO Q，LUO W，et al. A soluble NK⁃CAR medi⁃ ［J］. Leukemia，2018，32（2）：520-531
ates the specific cytotoxicity of NK cells toward the target ［30］ MASKALENKO N A，ZHIGAREV D，CAMPBELL K S.
CD20（+）lymphoma cells［J］. Aging Dis，2022，13（5）： Harnessing natural killer cells for cancer immunotherapy：
1576-1588 dispatching the first responders［J］. Nat Rev Drug Discov，
［19］ HUANG Y，ZENG J，LIU T，et al. DNAM1 and 2B4 co⁃ 2022，21（8）：559-577
stimulatory domains enhance the cytotoxicity of anti ⁃ ［31］ TSENG H C，XIONG W，BADETI S，et al. Efficacy of anti⁃
GPC3 chimeric antigen receptor ⁃ modified natural killer CD147 chimeric antigen receptors targeting hepatocellu⁃
cells against hepatocellular cancer cells in vitro［J］. Can⁃ lar carcinoma［J］. Nat Commun，2020，11（1）：4810
cer Manag Res，2020，12：3247-3255 ［32］ CHANG Y H，CONNOLLY J，SHIMASAKI N，et al. A chi⁃
［20］ SHI D，SHI Y，KASEB A O，et al. Chimeric antigen recep⁃ meric receptor with NKG2D specificity enhances natural
tor⁃glypican⁃3 T⁃cell therapy for advanced hepatocellular killer cell activation and killing of tumor cells［J］. Cancer
carcinoma：results of phase I trials［J］. Clin Cancer Res， Res，2013，73（6）：1777-1786
2020，26（15）：3979-3989 ［33］ 周肖英，林 彬，侯云华，等. miR⁃202及其靶基因Glyp⁃
［21］ CHOW V A，GOPAL A K，MALONEY D G，et al. Out⁃ ican⁃3 在肝癌中的表达及其临床意义［J］. 南京医科大
comes of patients with large B⁃cell lymphomas and pro⁃ 学学报（自然科学版），2021，41（3）：349-354
gressive disease following CD19⁃specific CAR T⁃cell ther⁃ ［34］ ZHU A X，GOLD P J，EL⁃KHOUEIRY A B，et al. First⁃in⁃
apy［J］. Am J Hematol，2019，94（8）：E209-E213 man phase I study of GC33，a novel recombinant human⁃
［22］ LEE E Y，JAKUBOVIC B D. IL⁃6 and cytokine release ized antibody against glypican ⁃ 3，in patients with ad⁃
syndrome：a new understanding in drug hypersensitivity vanced hepatocellular carcinoma［J］. Clin Cancer Res，
reactions［J］. Ann Allergy Asthma Immunol，2023，13 2013，19（4）：920-928
（2）：178-184 ［35］ WANG K，CHEN W，ZHANG Z，et al. CD147⁃spike pro⁃
［23］ ZHUANG X，VELTRI D P，LONG E O. Genome ⁃ wide tein is a novel route for SARS ⁃ CoV ⁃ 2 infection to host
CRISPR screen reveals cancer cell resistance to NK cells cells［J］. Signal Transduct Target Ther，2020，5（1）：283
induced by NK⁃derived IFN⁃gamma［J］. Front Immunol， ［36］ GENG J，CHEN L，YUAN Y，et al. CD147 antibody spe⁃
2019，10：2879 cifically and effectively inhibits infection and cytokine
［24］ LEE J Y，LEE E，HONG S W，et al. TCB2，a new anti⁃hu⁃ storm of SARS⁃CoV⁃2 and its variants delta，alpha，beta，
man interleukin⁃2 antibody，facilitates heterodimeric IL⁃2 and gamma［J］. Signal Transduct Target Ther，2021，6
receptor signaling and improves anti⁃tumor immunity［J］. （1）：347
Oncoimmunology，2020，9（1）：1681869 ［37］ JIN J，WANG S J，CUI J，et al. Hypo ⁃ phosphorylated
［25］ GROTE S，URENA⁃BAILEN G，CHAN K C，et al. In vi⁃ CD147 promotes migration and invasion of hepatocellular
tro evaluation of CD276⁃CAR NK⁃92 functionality，migra⁃ carcinoma cells and predicts a poor prognosis［J］. Cell
tion and invasion potential in the presence of immune in⁃ Oncol（Dordr），2019，42（4）：537⁃554
hibitory factors of the tumor microenvironment［J］. Cells， ［38］ XIAO W，ZHAO S，SHEN F，et al. Overexpression of
2021，10（5）：1020 CD147 is associated with poor prognosis，tumor cell mi⁃
［26］ SHI L，LIN H，LI G，et al. Cisplatin enhances NK cells im⁃ gration and ERK signaling pathway activation in hepato⁃
munotherapy efficacy to suppress HCC progression via al⁃ cellular carcinoma［J］. Exp Ther Med，2017，14（3）：
tering the androgen receptor（AR）⁃ ULBP2 signals［J］. 2637-2642
Cancer Lett，2016，373（1）：45-56 ［39］ LI J，HUANG Q，LONG X，et al. CD147 reprograms fatty
［27］ YU M，LUO H，FAN M，et al. Development of GPC3⁃spe⁃ acid metabolism in hepatocellular carcinoma cells
cific chimeric antigen receptor⁃engineered natural killer through Akt/mTOR/SREBP1c and P38/PPARalpha path⁃
cells for the treatment of hepatocellular carcinoma［J］. ways［J］. J Hepatol，2015，63（6）：1378-1389
Mol Ther，2018，26（2）：366-378 ［40］ PENG F，LI H，YOU Q，et al. CD147 as a novel prognos⁃
［28］ LIU M，HUANG W，GUO Y，et al. CAR NK⁃92 cells tar⁃ tic biomarker for hepatocellular carcinoma：a meta⁃analy⁃